0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > FGF-21

FGF-21

Brief Information

Name:Fibroblast growth factor 21
Target Synonym:FGF21
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:8
Lastest Research Phase:Phase 3 Clinical

Licensing

Project Name Modality Therapeutic Area Indications Stage Right Available
GIP/GLP-1/FGF21 Fusion Protein treating NASH, T2DM, Hyperlipoidemia NASH, T2DM, Hyperlipoidemia Preclinical

Product ListCompare or Buy

Par statut du produit :
Par catégorie de produit :
Par espèce :
Cat . Non Espèces Description du produit Structure Pureté Caractéristique
FG1-H82Q3 Human Biotinylated Human FGF-21 Protein, His,Avitag™
FG1-H82Q3-structure
FG1-H82Q3-sds
FG1-H5243 Human Human FGF-21 Protein, His Tag
FG1-H5243-structure
FG1-H5243-sds
ACRO Quality

Synonym Name

FGF-21, FGF21

Background

Fibroblast growth factor 21 (FGF21), which stimulates glucose uptake in differentiated adipocytes via the induction of glucose transporter SLC2A1/GLUT1 expression. FGF21 has been shown to protect animals from diet-induced obesity when overexpressed in transgenic mice. It also lowers blood glucose and triglyceride levels when administered to diabetic rodents, suggesting it may exhibit the therapeutic characteristics necessary for effective treatment of diabetes. Treatment of animals with FGF21 results in increased energy expenditure, fat utilisation and lipid excretion. FGF21 is most abundantly expressed in the liver, and also expressed in the thymus at lower levels.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Pegozafermin BIO89-100; TEV-47948 Phase 3 Clinical Teva Pharmaceutical Industries Ltd Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease Details
Efruxifermin AKR-001; AMG-876; EFX; Fc-FGF21(RGE) Phase 3 Clinical Amgen Inc Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus Details
Recombinant human FGF21 Fc fusion protein(Anyuan Pharmaceutical) AP-025 Phase 2 Clinical Anyuan Pharmaceutical Technology (Shanghai) Co Ltd Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease Details
HEC-88473 HEC-88473; HEC88473 Phase 2 Clinical Dongguan Hec Taigen Biopharmaceuticals Co Ltd Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Hepatitis; Obesity Details
YH-25724 YH-25724; YH25724 Phase 1 Clinical Yuhan Corp Metabolic Dysfunction-Associated Steatotic Liver Disease Details
AP-026 AP-026; TQA-2226; TQA2226; AP026 Phase 1 Clinical Anyuan Pharmaceutical Technology (Shanghai) Co Ltd Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Obesity; Hyperlipidemias; Overweight Details
Pegozafermin BIO89-100; TEV-47948 Phase 3 Clinical Teva Pharmaceutical Industries Ltd Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease Details
Efruxifermin AKR-001; AMG-876; EFX; Fc-FGF21(RGE) Phase 3 Clinical Amgen Inc Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus Details
Recombinant human FGF21 Fc fusion protein(Anyuan Pharmaceutical) AP-025 Phase 2 Clinical Anyuan Pharmaceutical Technology (Shanghai) Co Ltd Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease Details
HEC-88473 HEC-88473; HEC88473 Phase 2 Clinical Dongguan Hec Taigen Biopharmaceuticals Co Ltd Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Hepatitis; Obesity Details
YH-25724 YH-25724; YH25724 Phase 1 Clinical Yuhan Corp Metabolic Dysfunction-Associated Steatotic Liver Disease Details
AP-026 AP-026; TQA-2226; TQA2226; AP026 Phase 1 Clinical Anyuan Pharmaceutical Technology (Shanghai) Co Ltd Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Obesity; Hyperlipidemias; Overweight Details

This web search service is supported by Google Inc.

totop

Laisser un message